A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation
L Derosa, MA Bayar, L Albiges, G Le Teuff, B Escudier - Angiogenesis, 2019 - Springer
Background In patients with metastatic renal cell carcinoma (mRCC), the oncologic benefit
of second-line treatment for high volume tumors or presence of more than five risk factors …
of second-line treatment for high volume tumors or presence of more than five risk factors …
A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation
L Derosa, MA Bayar, L Albiges, G Le Teuff… - …, 2019 - pubmed.ncbi.nlm.nih.gov
Background In patients with metastatic renal cell carcinoma (mRCC), the oncologic benefit
of second-line treatment for high volume tumors or presence of more than five risk factors …
of second-line treatment for high volume tumors or presence of more than five risk factors …
A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation.
L Derosa, MA Bayar, L Albiges, G Le Teuff… - Angiogenesis, 2019 - europepmc.org
Background In patients with metastatic renal cell carcinoma (mRCC), the oncologic benefit
of second-line treatment for high volume tumors or presence of more than five risk factors …
of second-line treatment for high volume tumors or presence of more than five risk factors …
A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation
L Derosa, MA Bayar, L Albiges, G Le Teuff… - …, 2019 - search.proquest.com
Background In patients with metastatic renal cell carcinoma (mRCC), the oncologic benefit
of second-line treatment for high volume tumors or presence of more than five risk factors …
of second-line treatment for high volume tumors or presence of more than five risk factors …